Abstract: The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclyl or a 4-12 membered heterocyclyl containing 1-4 heteroatoms selected from O, N or S; B is any of the following groups (1) (2) or (3 ); C is any of the following groups (1') (2') (3") or (4') G1 is CH2, NH or O; G2 and G3 are, independently, is CH or N: Z is -C(O)-, -SO2-, -C1-3 alkyl- or -CH2-C(O)-; L is a bond, -C1-7 alkyl- or -C1-7 alkenyl-; The compounds of formula (I) are cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, for example androgen receptor or estrogen receptor, dependent diseases and conditions, such as cancer including prostate cancer and estrogen cancer.
| # | Name | Date |
|---|---|---|
| 1 | 202317043616-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [29-06-2023(online)].pdf | 2023-06-29 |
| 2 | 202317043616-STATEMENT OF UNDERTAKING (FORM 3) [29-06-2023(online)].pdf | 2023-06-29 |
| 3 | 202317043616-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [29-06-2023(online)].pdf | 2023-06-29 |
| 4 | 202317043616-FORM 1 [29-06-2023(online)].pdf | 2023-06-29 |
| 5 | 202317043616-DECLARATION OF INVENTORSHIP (FORM 5) [29-06-2023(online)].pdf | 2023-06-29 |
| 6 | 202317043616-COMPLETE SPECIFICATION [29-06-2023(online)].pdf | 2023-06-29 |
| 7 | 202317043616-FORM-26 [05-09-2023(online)].pdf | 2023-09-05 |
| 8 | 202317043616-Proof of Right [30-11-2023(online)].pdf | 2023-11-30 |
| 9 | 202317043616-FORM 3 [27-12-2023(online)].pdf | 2023-12-27 |
| 10 | 202317043616-FORM 18 [21-11-2024(online)].pdf | 2024-11-21 |